查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2099674

藥物研發外包市場－2026-2032年全球市場預測

Drug Discovery Outsourcing Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥物研發外包市場將成長至 77.1 億美元，複合年成長率為 8.71%。

主要市場統計數據
基準年 2025 42.9億美元
預計年份：2026年 46.5億美元
預測年份 2032 77.1億美元
複合年成長率 (%) 8.71%

藥物研發執行摘要

藥物研發外包已成為製藥公司、生技公司和學術研究機構的策略性商業模式，旨在提供從標靶識別到先導先導化合物最佳化和臨床前決策的更快速、更靈活、更專業的解決方案。此模式涵蓋藥物化學、生物服務、藥物動力學、毒理學、電腦輔助藥物發現、檢測方法開發、生物標記研究以及整合式藥物研發計畫。這種需求的形成源於療法的日益複雜化、持續提升研發效率的壓力，以及在不永久性擴充內部基礎設施的情況下利用專業科學知識的需求。外包合作夥伴的角色正日益從單純的交易服務供應商轉變為創新合作者，為小分子藥物、生物製藥、細胞和基因治療基礎技術、基於RNA的方法以及精準醫療計畫提供支援。在這種環境下，客戶優先考慮科學深度、可重複性、資料完整性、智慧財產權保護、監管合規性以及將實驗室實驗與數位化藥物研發工作流程整合的能力。

藥物研發外包環境的變革性變化

藥物研發外包格局正經歷著從單純基於能力的合約轉變為整合式、技術主導合作的結構性。贊助公司擴大將選定的藥物研發活動與合作夥伴整合，這些合作夥伴能夠將標靶驗證、先導化合物檢驗、化學最佳化、體外和體內生物學、藥物代謝和藥物動力學以及轉化科學整合到協調的企劃團隊中。日益抗體藥物複合體。監管機構對資料品質、可追溯性、模型有效性和良好實驗室規範 (GLP) 標準的要求也在重塑外包決策，贊助公司尋求擁有檢驗的平台、標準化文件和健全的品管系統的合作夥伴。同時，地緣政治因素、供應鏈韌性、生物安全意識和資料保護要求正迫使各組織將其服務網路擴展到成熟和新興的研究地點。競爭優勢正向那些擁有科學專業知識、靈活的合約模式、自動化、資訊學和透明管治的合作夥伴轉移。

人工智慧對藥物研發外包的累積影響

人工智慧 (AI) 透過提高假設生成的速度、規模和準確性，對藥物研發外包整體產生了累積影響，同時也對資料管治和實驗檢驗提出了新的要求。人工智慧驅動的工具正被應用於標靶辨識、文獻挖掘、體學分析、虛擬篩檢、從頭分子設計、ADMET 預測、蛋白質結構分析、基於影像的表現型篩檢和臨床適用性評估。蛋白質結構預測、高內涵篩檢分析、生成化學和聯邦學習等領域的公開進展增強了人們對人工智慧驅動的藥物研發的信心，但可重複性、偏差控制、可解釋性和模型檢驗仍然至關重要。最有效的藥物研發外包模式並非將人工智慧作為專家經驗的替代品，而是將其作為補充層，將計算預測與迭代的實驗室檢驗相結合。贊助商越來越注重評估外包合作夥伴，評估標準包括：精心整理的資料集品質、演算法工作流程的可審計性、網路安全措施、資料隱私法規的遵守情況，以及將人工智慧產生的輸出轉化為經實驗驗證的先導化合物的能力。隨著人工智慧應用的不斷擴展，外包關係也變得更加資料密集、跨職能和以里程碑主導。

全球藥物研發外包的關鍵區域洞察

亞太地區是藥物研發外包的主要成長引擎，這得益於其豐富的科研人才、不斷發展的生物技術生態系統以及在化學、生物學和臨床前研究方面的強大實力。中國和印度仍然是該地區合約研究的中心，而日本、韓國、新加坡和澳洲則擁有先進的生物醫學研究、轉化科學、成熟的監管體系和高品質的臨床研究基礎設施。北美憑藉其強大的製藥和生物技術研發管線、強勁的創業投資驅動創新、先進的學術醫療中心以及廣泛的產學合作，仍然是高價值外包需求的中心。美國透過外包對藥物研發策略保持著特別強大的影響力，而加拿大則充分利用其在人工智慧驅動的研究、生物製藥、基因組學和轉化醫學方面的優勢。拉丁美洲因其臨床和轉化能力、生物多樣性相關研究機會以及成本效益高的科學研究管理而備受關注，其中巴西和墨西哥是該地區生命科學活動的關鍵中心。歐洲的特點是擁有先進的法規結構、強大的公共研究機構，以及在藥物化學、生技藥品、腫瘤學、免疫學和罕見疾病研究方面的專業知識，並得到歐盟內部協調一致的政策結構的支持，從而促進了跨境合作。在中東，作為國家多元化策略的一部分，對生物技術、基因組學和醫療保健創新領域的投資正在穩步推進，尤其是在海灣國家，精準醫療和研究基礎設施的建設正在蓬勃發展。在非洲，不斷擴展的研究網路和公共衛生優先事項正在為感染疾病研究、基因組學、流行病學、疫苗科學以及針對特定族群的生物醫學見解創造新的機會。

來自影響藥物研發外包策略的關鍵群體的見解

東協憑藉其生物醫學研究基礎設施、區域臨床網路以及對政府主導的生命科學舉措的投資，在藥物研發外包領域發揮著日益重要的作用，其中新加坡是轉化研究、資料科學和生物製藥領域合作的領先中心。海灣合作理事會（GCC）成員國正透過以基因組醫學、研究基礎設施、數位健康以及本土生命科學能力發展為重點的國家戰略，推動生物技術和醫療保健領域的創新，從而為精準醫療和夥伴關係研究領域的專業外包合作創造了機會。歐盟透過統一的監管標準、研究資助機制、資料保護法規和跨境科學合作，為藥物研發外包提供了一個協調的環境，使其對尋求合規性和創新主導夥伴關係的贊助商極具吸引力。金磚國家（中國、印度、巴西、俄羅斯和南非）擁有科研規模、與生產製造相關的研究能力、多元化的患者群體以及不斷發展的生物技術生態系統，儘管各國在監管、地緣政治和數據傳輸方面的考量各不相同。七國集團（G7）憑藉其成熟的製藥業、先進的監管體系、健全的智慧財產權框架和領先的學術研究機構，在高價值藥物研發外包領域繼續發揮核心作用。北約成員國與已建立的生物製藥創新走廊高度重合，因此，對於管理高度敏感藥物研發資產的申辦方而言，安全的數據處理、穩健的供應鏈、網路風險管理以及值得信賴的研究夥伴關係變得日益重要。

主要國家藥物研發外包趨勢

美國是藥物研發外包的重要樞紐，擁有許多生技公司、製藥研究中心、大學醫學中心、創業投資資金和專業創新叢集。加拿大在人工智慧驅動的藥物研發、生技藥品、神經科學、腫瘤學、基因組學和轉化醫學研究方面擁有豐富的專業知識，並與大學和生命科學公司建立了牢固的合作關係。墨西哥憑藉其與北美贊助商的地理接近性、增強的科研服務和不斷提升的醫療保健研究能力，正在擴大其影響力。巴西是拉丁美洲的生命科學中心，擁有成熟的生物醫學研究機構、生物多樣性支持的藥物研發潛力以及公共衛生研究重點。英國在早期藥物研發、基因組學、腫瘤學、神經科學和轉化醫學領域仍然具有影響力，這得益於其強大的學術基礎和完善的監管體系。德國在化學、工程、生技藥品、實驗室自動化和精準醫療方面實力雄厚，而法國則在先進的生物醫學研究、免疫學、腫瘤學和公私科學合作方面做出了貢獻。俄羅斯在化學、生物學和特定治療領域的研究實力雄厚，但地緣政治因素和合規性考量限制了其國際參與。義大利和西班牙擁有強大的學術研究網路、腫瘤學和罕見疾病領域的實力，以及蓬勃發展的生物技術生態系統。中國憑藉其大規模的科學研究實力和快速發展的生物技術，已成為全球領先的化學、生物學、毒理學和綜合藥物研發服務外包中心。印度在藥物化學、計算化學、生物服務、藥理學和具成本效益的綜合藥物研發運作方面極具競爭力。日本致力於高品質的藥物科學、再生醫學、治療創新和先進的轉化研究，而澳洲則以其臨床應用、免疫學、腫瘤學、感染疾病研究和高水平的研究而聞名。在生命科學基礎設施協調投資的支持下，韓國正在崛起為生物製藥、細胞療法、數位醫療和先進生物醫學創新領域的領導力量。

為藥物研發外包領域的領導者提供的實用建議

產業領導者應將藥物研發外包視為創新驅動力的策略延伸，而不僅僅是採購職能。申辦方應根據科學重要性、智慧財產權保密性、模式複雜性、資料保密性和所需技術深度對外包需求進行分類，並選擇在可重複性科學、資料完整性和跨學科執行能力方面擁有良好記錄的合作夥伴。管治模式應包括明確的決策權、明確的里程碑、品質預期、資料標準、檢體儲存歷史管理和升級程序。各機構應透過評估科學出版物、合格檢查歷史（如適用）、平台驗證、網路安全措施、智慧財產權管理、業務永續營運計劃以及成功的技術轉移記錄來加強合作夥伴的資格篩選。人工智慧驅動的外包應以透明的模型文件、精心選擇的訓練資料、實驗檢驗、偏差緩解和可審計的計算工作流程為支援。為降低營運風險，申辦方應考慮地理分散的網路、關鍵職能的雙源方案以及應對供應鏈、出口管制、資料本地化或政策中斷的緊急時應對計畫。領導者還應該投資於可互通的資料架構、安全的協作環境以及基於結果的績效指標，將外包活動與專案進度聯繫起來，而不僅僅是數量。

藥物發現外包的調查方法

本執行摘要基於系統性的二手研究方法，採用經核實的公共領域資源，包括監管指南、同行檢驗的科學文獻、政府生命科學策略、臨床和生物醫學研究途徑出版物、行業協會資料、專利和科學資料庫趨勢，以及人工智慧、生物技術和合約研究組織 (CRO) 領域的已記錄進展。資訊來源在多個資訊來源類別中進行交叉比對，以識別技術採納、區域能力、治療模式複雜性、外包管治和研究基礎設施發展方面的一致模式。本分析強調基於證據的定性解讀，不涉及市場規模估算、市場規模計算、市場佔有率和預測。研究整合了區域、群體和國家觀點，並基於已記錄的研究能力、監管成熟度、科學專長、創新基礎設施、人才儲備、數據管治環境和生命科學政策趨勢。調查方法優先考慮資料的完整性、及時性、相關性和可追溯性，同時排除未經證實的說法、宣傳定位和檢驗的競爭對手資訊。

結論：藥物研發外包的策略展望

藥物研發外包正逐漸成為企業在日益複雜的治療產品線中尋求科學敏捷性、專業知識和更快證據產生的核心策略能力。這一領域正受到整合服務模式、人工智慧驅動的藥物研發工作流程、對品質和資料管治日益成長的期望以及研究能力地域分散化等因素的重塑。儘管北美和歐洲仍然是高價值創新和監管成熟度的核心，但亞太地區作為關鍵藥物研發合作夥伴的角色正在不斷擴大。拉丁美洲、中東和非洲的新興機會正在進一步深化全球外包生態系統。成功的關鍵在於選擇能夠將先進科學、成熟的數位化工具、安全的資料管理、強大的品質系統和透明的合作模式結合的合作夥伴。那些能夠將外包策略與產品組合優先順序、風險管理、合規要求和轉化決策相協調的企業，將更有利於提高研究效率並推動差異化候選療法的開發。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 藥物研發外包市場：依服務類型分類

  • 生物服務
    • 檢測方法開發
    • 生物學測試
  • 化學服務
    • 客製合成
    • 製程研究與開發；
  • 資料管理服務
    • 生物資訊學
    • 資料整合

第8章 藥物研發外包市場：依藥物研發階段分類

  • 先導藥物最適化
    • 化合物篩檢
    • 基於結構的藥物發現設計
  • 目標識別
    • 生物標記發現
    • 基因測序方法

第9章 藥物研發外包市場：依工作流程分類

  • 先導化合物的篩選與最佳化
  • 臨床前開發
  • 目標識別和篩檢
  • 目標檢驗和功能資訊學

第10章 藥物研發外包市場：依藥物類型分類

  • 聚合物化合物
    • 生物製劑
    • 生物相似藥
  • 低分子化合物

第11章：藥物研發外包市場：依應用領域分類

  • 心血管疾病
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌

第12章 藥物研發外包市場：依最終用戶分類

  • 受託研究機構
  • 製藥和生物技術公司
  • 研究機構

第13章 藥物研發外包市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 藥物研發外包市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 藥物研發外包市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Agilent Technologies Inc.
  • Aragen Life Sciences Ltd.
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • GenScript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • IQVIA
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Services
  • Personalis, Inc.
  • Pfizer Inc.
  • PPD Inc.
  • Promega Corporation
  • Revvity Discovery Limited
  • Sanofi SA
  • STC Biologics Inc.
  • Syngene International Ltd.
  • TCG Lifesciences Pvt. Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-742BD517D92E

The Drug Discovery Outsourcing Market is projected to grow by USD 7.71 billion at a CAGR of 8.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.29 billion
Estimated Year [2026] USD 4.65 billion
Forecast Year [2032] USD 7.71 billion
CAGR (%) 8.71%

Drug Discovery Outsourcing Executive Summary

Drug discovery outsourcing has become a strategic operating model for pharmaceutical, biotechnology, and academic research organizations seeking faster, more flexible, and more specialized paths from target identification to lead optimization and preclinical decision-making. The model spans medicinal chemistry, biology services, pharmacokinetics, toxicology, computational drug design, assay development, biomarker research, and integrated discovery programs. Demand is being shaped by the rising complexity of therapeutic modalities, persistent pressure to improve R&D productivity, and the need to access specialized scientific capabilities without permanently expanding internal infrastructure. Outsourcing partners increasingly function as innovation collaborators rather than transactional service providers, supporting small molecules, biologics, cell and gene therapy enablers, RNA-based approaches, and precision medicine programs. In this environment, buyers prioritize scientific depth, reproducibility, data integrity, intellectual property protection, regulatory readiness, and the ability to integrate wet-lab experimentation with digital discovery workflows.

Transformative Shifts in the Drug Discovery Outsourcing Landscape

The drug discovery outsourcing landscape is undergoing a structural shift from capacity-based contracting toward integrated, technology-enabled collaboration. Sponsors are increasingly consolidating selected discovery activities with partners that can connect target validation, hit identification, chemistry optimization, in vitro and in vivo biology, drug metabolism and pharmacokinetics, and translational science within coordinated project teams. This shift is being accelerated by more complex pipelines, including difficult-to-drug targets, protein degradation, bispecifics, antibody-drug conjugates, nucleic acid therapeutics, and immunology-focused programs. Regulatory expectations for data quality, traceability, model relevance, and good laboratory practice alignment are also reshaping outsourcing decisions, as sponsors seek partners with validated platforms, standardized documentation, and strong quality systems. At the same time, geopolitical considerations, supply chain resilience, biosecurity awareness, and data protection requirements are pushing organizations to diversify service networks across established and emerging research hubs. The competitive advantage is moving toward partners that combine scientific specialization, flexible engagement models, automation, informatics, and transparent governance.

Cumulative Impact of Artificial Intelligence on Drug Discovery Outsourcing

Artificial intelligence is exerting a cumulative impact across drug discovery outsourcing by improving the speed, scale, and precision of hypothesis generation while creating new requirements for data governance and experimental validation. AI-enabled tools are being applied to target identification, literature mining, omics interpretation, virtual screening, de novo molecule design, ADMET prediction, protein structure analysis, image-based phenotypic screening, and clinical translatability assessments. Publicly documented advances in protein structure prediction, high-content screening analytics, generative chemistry, and federated learning have strengthened confidence in AI-assisted discovery, but reproducibility, bias control, explainability, and model validation remain essential. The most effective outsourcing models use artificial intelligence as an augmentation layer rather than a substitute for domain expertise, linking computational predictions with iterative wet-lab validation. Sponsors increasingly evaluate outsourcing partners on the quality of curated datasets, auditability of algorithmic workflows, cybersecurity controls, compliance with data privacy rules, and the ability to convert AI-derived outputs into experimentally confirmed leads. As AI adoption expands, outsourcing relationships are becoming more data-intensive, cross-functional, and milestone-driven.

Key Regional Insights Across Global Drug Discovery Outsourcing

Asia-Pacific is a major growth engine for drug discovery outsourcing, supported by deep scientific talent pools, expanding biotechnology ecosystems, and strong capabilities in chemistry, biology, and preclinical research. China and India remain central to the region's contract research activity, while Japan, South Korea, Singapore, and Australia contribute advanced biomedical research, translational science, regulatory maturity, and high-quality clinical research infrastructure. North America continues to be a high-value outsourcing demand center due to dense pharmaceutical and biotechnology pipelines, strong venture-backed innovation, advanced academic medical centers, and extensive academic-industry collaboration. The United States remains particularly influential in outsourced discovery strategy, while Canada contributes strengths in AI-enabled research, biologics, genomics, and translational medicine. Latin America is gaining attention for clinical and translational capabilities, biodiversity-linked research opportunities, and cost-efficient scientific operations, with Brazil and Mexico acting as important anchors for regional life sciences activity. Europe is characterized by advanced regulatory frameworks, strong public research institutions, and expertise in medicinal chemistry, biologics, oncology, immunology, and rare disease research, with cross-border collaboration supported by harmonized policy structures within the European Union. The Middle East is investing in biotechnology, genomics, and healthcare innovation as part of national diversification strategies, particularly across Gulf economies building precision medicine and research infrastructure. Africa presents emerging opportunities in infectious disease research, genomics, epidemiology, vaccine science, and population-specific biomedical insights, supported by growing research networks and public health priorities.

Key Group Insights Shaping Drug Discovery Outsourcing Strategies

ASEAN is becoming more relevant to drug discovery outsourcing through investments in biomedical research infrastructure, regional clinical networks, and government-backed life sciences initiatives, with Singapore serving as a prominent hub for translational research, data science, and biopharmaceutical collaboration. The GCC is advancing biotechnology and healthcare innovation through national strategies focused on genomic medicine, research infrastructure, digital health, and localized life sciences capability development, creating opportunities for specialized outsourcing partnerships in precision medicine and translational research. The European Union provides a coordinated environment for drug discovery outsourcing through harmonized regulatory standards, research funding mechanisms, data protection rules, and cross-border scientific collaboration, making it attractive for sponsors seeking compliance-oriented and innovation-driven partnerships. BRICS economies contribute a combination of scientific scale, manufacturing-adjacent research capabilities, diverse patient populations, and expanding biotechnology ecosystems across China, India, Brazil, Russia, and South Africa, although regulatory, geopolitical, and data-transfer considerations vary by country. G7 countries remain central to high-value discovery outsourcing because of mature pharmaceutical sectors, advanced regulatory systems, strong intellectual property frameworks, and leading academic research institutions. NATO member countries overlap significantly with established biopharmaceutical innovation corridors, where secure data handling, resilient supply chains, cyber-risk management, and trusted research partnerships are increasingly important for sponsors managing sensitive discovery assets.

Key Country Insights for Drug Discovery Outsourcing

The United States is a leading demand center for drug discovery outsourcing, supported by a large concentration of biotechnology companies, pharmaceutical research sites, academic medical centers, venture financing, and specialized innovation clusters. Canada contributes expertise in AI-assisted drug discovery, biologics, neuroscience, oncology, genomics, and translational research, with strong links between universities and life sciences enterprises. Mexico is strengthening its role through proximity to North American sponsors, expanding scientific services, and healthcare research capabilities. Brazil anchors Latin American life sciences activity with established biomedical research institutions, biodiversity-linked discovery potential, and public health research priorities. The United Kingdom remains influential in early-stage discovery, genomics, oncology, neuroscience, and translational medicine, supported by a strong academic base and established regulatory capabilities. Germany offers deep strengths in chemistry, engineering, biologics, laboratory automation, and precision medicine, while France contributes advanced biomedical research, immunology, oncology, and public-private scientific collaboration. Russia maintains research depth in chemistry, biology, and selected therapeutic areas, although geopolitical and compliance considerations influence international engagement. Italy and Spain provide strong academic research networks, oncology and rare disease capabilities, and growing biotechnology ecosystems. China is a major global hub for outsourced chemistry, biology, toxicology, and integrated discovery services, supported by large scientific capacity and rapid biotechnology expansion. India is highly competitive in medicinal chemistry, computational chemistry, biology services, pharmacology, and cost-efficient integrated discovery operations. Japan contributes high-quality pharmaceutical science, regenerative medicine, modality innovation, and advanced translational research, while Australia is recognized for clinical translation, immunology, oncology, infectious disease research, and research quality. South Korea is emerging as a strong player in biologics, cell therapy, digital health, and advanced biomedical innovation, supported by coordinated investment in life sciences infrastructure.

Actionable Recommendations for Drug Discovery Outsourcing Leaders

Industry leaders should treat drug discovery outsourcing as a strategic extension of the innovation engine rather than a procurement-only function. Sponsors should segment outsourcing needs by scientific criticality, intellectual property sensitivity, modality complexity, data sensitivity, and required technology depth, then select partners with proven capabilities in reproducible science, data integrity, and multidisciplinary execution. Governance models should include clear decision rights, milestone definitions, quality expectations, data standards, sample chain-of-custody controls, and escalation pathways. Organizations should strengthen partner qualification by assessing scientific publications, regulatory inspection history where applicable, platform validation, cybersecurity practices, intellectual property controls, business continuity planning, and evidence of successful technology transfer. AI-enabled outsourcing should be supported by transparent model documentation, curated training data, experimental confirmation, bias mitigation, and audit-ready computational workflows. To reduce operational risk, sponsors should consider geographically diversified networks, dual-source options for critical capabilities, and contingency plans for supply chain, export control, data localization, or policy disruption. Leaders should also invest in interoperable data architecture, secure collaboration environments, and outcome-based performance metrics that connect outsourced activities to program progression rather than activity volume alone.

Research Methodology for Drug Discovery Outsourcing Insights

This executive summary is developed through a structured secondary research approach using verified public-domain sources, including regulatory guidance, peer-reviewed scientific literature, government life sciences strategies, clinical and biomedical research publications, industry association materials, patent and scientific database trends, and documented developments in artificial intelligence, biotechnology, and contract research operations. Insights are triangulated across multiple source categories to identify consistent patterns in technology adoption, regional capabilities, therapeutic modality complexity, outsourcing governance, and research infrastructure development. The analysis emphasizes evidence-backed qualitative interpretation and excludes market estimation, market sizing, market share, and forecasting. Regional, group, and country perspectives are synthesized based on documented research capacity, regulatory maturity, scientific specialization, innovation infrastructure, workforce depth, data governance environment, and life sciences policy activity. The methodology prioritizes data integrity, recency, relevance, and traceability while avoiding unsupported claims, promotional positioning, and unverified competitive references.

Conclusion: Strategic Outlook for Drug Discovery Outsourcing

Drug discovery outsourcing is evolving into a core strategic capability for organizations seeking scientific agility, specialized expertise, and faster evidence generation across increasingly complex therapeutic pipelines. The sector is being reshaped by integrated service models, AI-enabled discovery workflows, higher expectations for quality and data governance, and the geographic diversification of research capabilities. North America and Europe remain central to high-value innovation and regulatory maturity, while Asia-Pacific continues to expand its role as a critical discovery and development partner. Emerging opportunities across Latin America, the Middle East, and Africa add further depth to the global outsourcing ecosystem. Success will depend on selecting partners that combine advanced science, validated digital tools, secure data practices, robust quality systems, and transparent collaboration models. Organizations that align outsourcing strategy with portfolio priorities, risk management, compliance requirements, and translational decision-making will be better positioned to improve research productivity and advance differentiated therapeutic candidates.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Discovery Outsourcing Market, by Service Type

  • 7.1. Introduction
  • 7.2. Biological Services
    • 7.2.1. Assay Development
    • 7.2.2. Biological Testing
  • 7.3. Chemical Services
    • 7.3.1. Custom Synthesis
    • 7.3.2. Process R&D
  • 7.4. Data Management Services
    • 7.4.1. Bioinformatics
    • 7.4.2. Data Integration

8. Drug Discovery Outsourcing Market, by Discovery Phase

  • 8.1. Introduction
  • 8.2. Lead Optimization
    • 8.2.1. Compound Screening
    • 8.2.2. Structure-Based Drug Design
  • 8.3. Target Identification
    • 8.3.1. Biomarker Discovery
    • 8.3.2. Genomic Sequencing Methods

9. Drug Discovery Outsourcing Market, by Workflow

  • 9.1. Introduction
  • 9.2. Lead Identification & Candidate Optimization
  • 9.3. Preclinical Development
  • 9.4. Target Identification & Screening
  • 9.5. Target Validation & Functional Informatics

10. Drug Discovery Outsourcing Market, by Drug Type

  • 10.1. Introduction
  • 10.2. Large Molecules
    • 10.2.1. Biologics
    • 10.2.2. Biosimilar
  • 10.3. Small Molecules

11. Drug Discovery Outsourcing Market, by Application Area

  • 11.1. Introduction
  • 11.2. Cardiovascular Diseases
    • 11.2.1. Heart Failure
    • 11.2.2. Hypertension
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Viral Infections
  • 11.4. Oncology
    • 11.4.1. Hematological Malignancies
    • 11.4.2. Solid Tumors

12. Drug Discovery Outsourcing Market, by End User

  • 12.1. Introduction
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical & Biotechnology Companies
  • 12.4. Research Institutes

13. Drug Discovery Outsourcing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Drug Discovery Outsourcing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Outsourcing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Agilent Technologies Inc.
  • 17.2. Aragen Life Sciences Ltd.
  • 17.3. BPS Bioscience, Inc.
  • 17.4. Celentyx Ltd.
  • 17.5. Charles River Laboratories International, Inc.
  • 17.6. Covance, Inc.
  • 17.7. Crown Bioscience, Inc.
  • 17.8. Curia Global, Inc.
  • 17.9. Dalton Pharma Services
  • 17.10. Eurofins Scientific
  • 17.11. Evotec SE
  • 17.12. Explicyte
  • 17.13. GenScript Biotech Corporation
  • 17.14. HD Biosciences Co., Ltd.
  • 17.15. IQVIA
  • 17.16. Jubilant Biosys Ltd.
  • 17.17. Laboratory Corporation of America Holdings
  • 17.18. Merck & Co., Inc.
  • 17.19. Oncodesign Services
  • 17.20. Personalis, Inc.
  • 17.21. Pfizer Inc.
  • 17.22. PPD Inc.
  • 17.23. Promega Corporation
  • 17.24. Revvity Discovery Limited
  • 17.25. Sanofi S.A.
  • 17.26. STC Biologics Inc.
  • 17.27. Syngene International Ltd.
  • 17.28. TCG Lifesciences Pvt. Limited
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASSAY DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ASSAY DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASSAY DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHEMICAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHEMICAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHEMICAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CUSTOM SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CUSTOM SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CUSTOM SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROCESS R&D MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROCESS R&D MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROCESS R&D MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DATA MANAGEMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DATA MANAGEMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DATA MANAGEMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOINFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOINFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOINFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DATA INTEGRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DATA INTEGRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DATA INTEGRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LEAD OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPOUND SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPOUND SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPOUND SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STRUCTURE-BASED DRUG DESIGN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STRUCTURE-BASED DRUG DESIGN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STRUCTURE-BASED DRUG DESIGN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGET IDENTIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOMIC SEQUENCING METHODS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOMIC SEQUENCING METHODS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOMIC SEQUENCING METHODS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGET IDENTIFICATION & SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGET IDENTIFICATION & SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGET IDENTIFICATION & SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGET VALIDATION & FUNCTIONAL INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGET VALIDATION & FUNCTIONAL INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGET VALIDATION & FUNCTIONAL INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LARGE MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LARGE MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LARGE MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOSIMILAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOSIMILAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOSIMILAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 232. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 234. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 235. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 239. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 240. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 283. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 284. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 285. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 287. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 288. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 289. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 293. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 297. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 299. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 300. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 301. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 303. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 304. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 305. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. NATO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA DRUG DISCOVERY OUTSOURCING MARKE